Cas:350818-62-1 [(2R)-3-carboxy-2-hydroxypropyl]-dimethyl-(trideuteriomethyl)azanium,chloride manufacturer & supplier

Chemical Name:[(2R)-3-carboxy-2-hydroxypropyl]-dimethyl-(trideuteriomethyl)azanium,chloride

CAS.NO:350818-62-1

Synonyms:L-Carnitine-methyl-d3 hydrochloride

Molecular Formula:C₆H₁₁ClD₃NO₃

Molecular Weight:186.65200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:60.77000

Exact Mass:186.08500

LogP:0.18560

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like L-Carnitine-methyl-d3 hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-Carnitine-methyl-d3 hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-Carnitine-methyl-d3 hydrochloride Use and application,L-Carnitine-methyl-d3 hydrochloride technical grade,usp/ep/jp grade.

Related News: ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. [(2R)-3-carboxy-2-hydroxypropyl]-dimethyl-(trideuteriomethyl)azanium,chloride manufacturer Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). [(2R)-3-carboxy-2-hydroxypropyl]-dimethyl-(trideuteriomethyl)azanium,chloride supplier What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. [(2R)-3-carboxy-2-hydroxypropyl]-dimethyl-(trideuteriomethyl)azanium,chloride vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. [(2R)-3-carboxy-2-hydroxypropyl]-dimethyl-(trideuteriomethyl)azanium,chloride factory According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017).